Browse the evidence

Short-chain fatty acids (SCFAs) produced by gut bacteria have complex effects: while generally beneficial for blood pressure regulation via GPCR activation, increased production in obesity may contribute to calorie harvest and weight gain.

Fiber is good for your heart, but if you are struggling with weight, be aware that your gut bacteria might be extracting more calories from your food. Focus on a balanced diet rather than just maximizing fiber intake if weight loss is a primary goal.

Online marketing of GLP-1 receptor agonists as 'weight loss injections' creates unrealistic expectations and encourages off-label, non-medical use, posing significant public health risks.

Be skeptical of online content that promotes GLP-1 injections as 'weight loss injections' without mentioning medical indications, side effects, or the need for a prescription. These are serious medications for obesity management, not cosmetic shortcuts. Consult a healthcare provider to determine if you are a suitable candidate and to understand the risks and benefits.

Activation of the mitochondrial unfolded protein response (UPRmt) in adipocytes serves as a critical adaptive mechanism to restore mitochondrial proteostasis and mitigate dysfunction during metabolic stress, offering a potential therapeutic strategy for obesity and related metabolic disorders.

This paper highlights that your body has a sophisticated internal repair system (UPRmt) that activates when mitochondria are stressed. While there is no specific 'dose' provided, the text suggests that factors like cold exposure, exercise, and specific hormonal signals can induce 'browning' of white fat and activate these pathways. To support this mechanism, focus on activities known to stimulate mitochondrial biogenesis and stress adaptation, such as regular physical exercise and potentially cold exposure, as these are linked to the activation of UPRmt and improved metabolic health in the reviewed literature.

Greater lean body mass loss with tirzepatide is mechanistically linked to its dual GLP-1/GIP receptor agonism, as GIP receptors are broadly expressed in immune, stromal, and vascular muscle compartments, unlike the more restricted GLP-1 receptor.

Tirzepatide's unique ability to activate GIP receptors may affect muscle tissue differently than semaglutide by influencing immune and vascular cells in muscle, potentially contributing to greater muscle loss.

Improvement in cellulite severity is not significantly correlated with changes in body weight or fat mass, indicating that local structural and metabolic-dermal interventions are primary drivers of cellulite reduction rather than systemic adiposity loss.

If you are trying to reduce cellulite, relying solely on weight loss or fat loss may not yield visible improvements in skin texture. This study suggests that combining systemic metabolic health (e.g., managing insulin/inflammation) with targeted local treatments (like specific topical formulations) is more effective for cellulite than weight loss alone. Focus on local tissue health and metabolic balance rather than just the scale.

Gut microbiota dysbiosis impairs GLP-1 secretion, contributing to the progression of degenerative musculoskeletal diseases (osteoarthritis, osteoporosis, sarcopenia, and intervertebral disc degeneration).

Degenerative joint and muscle issues in aging may be linked to gut health. Restoring a healthy gut microbiome through diet (fiber/prebiotics), probiotics, or fecal microbiota transplantation (FMT) may help restore natural GLP-1 levels, potentially slowing disease progression. This is a supportive strategy, not a standalone cure.

GLP-1 exerts protective effects on musculoskeletal tissues (bone, cartilage, muscle, disc) by reducing inflammation, oxidative stress, and apoptosis.

Maintaining healthy GLP-1 levels (via gut health) may help protect joints and muscles from age-related degeneration by reducing inflammation and cell death.

Current economic models often undervalue incretin therapies by excluding downstream benefits (e.g., reduced MACE, sleep apnea, osteoarthritis), leading to high ICERs that may exceed willingness-to-pay thresholds without price reductions.

For payers, these drugs are expensive. However, if you account for long-term health savings (fewer heart attacks, surgeries), they can be cost-effective, especially if the price is lowered or targeted at high-risk patients.

GLP-1 receptor agonists delay gastric emptying via peripheral and central nervous system pathways, creating a significant risk of retained gastric contents and pulmonary aspiration during anesthesia even when standard preoperative fasting guidelines are followed.

If you take a GLP-1 medication (like Ozempic, Wegovy, or Mounjaro) and are scheduled for surgery, you must inform your anesthesiologist and endocrinologist. Do not assume standard fasting rules apply. Your stomach may still contain food, increasing the risk of serious lung complications during anesthesia. Your care team may need to adjust your fasting instructions, postpone elective surgery, or use special techniques to protect your airway.

Short-acting GLP-1 RAs cause more pronounced delays in gastric emptying than long-acting agents, although long-acting agents may still pose aspiration risks due to residual effects depending on dose and treatment duration.

Know which GLP-1 medication you take. Short-acting drugs (like Byetta or Trulicity's short-acting cousin) tend to slow your stomach more than long-acting ones (like Ozempic or Mounjaro). However, even long-acting drugs can keep food in your stomach if you took a dose recently. Always tell your surgical team exactly when you took your last dose.

In non-beta tissues (liver, kidney, skeletal muscle, adipose), the mitochondrial benefits of GLP-1RAs are likely a combination of direct receptor signaling and indirect systemic improvements such as weight loss and reduced inflammation.

While GLP-1 drugs improve mitochondrial health in organs like the liver and muscles, these benefits are partly due to the overall reduction in body weight and blood sugar. It is a combined effect of losing weight and the drug's direct action on cells.

Atomoxetine and oxybutynin combination reduces AHI in OSA patients but may increase heart rate and blood pressure, requiring risk/benefit assessment.

A combination of atomoxetine and oxybutynin can slightly reduce sleep apnea severity, but it may raise heart rate and blood pressure. Because the benefit is small and risks exist, it is not a first-line treatment and requires careful medical supervision.

The integration of digital health and artificial intelligence is expected to advance antiobesity drug development.

Practitioners should consider how digital health tools and AI may enhance treatment strategies for obesity.

Those who reported use of prescription weight loss medication were significantly older and had significantly higher body mass index compared to those who did not report use.

Practitioners should consider age and BMI when assessing patients for prescription weight loss medications.

Eating disorder attitudes and behaviors were more prevalent among boys and men who used prescription weight loss medication.

Practitioners should monitor for eating disorder symptoms in patients using prescription weight loss medications.

40.4% of gym users in Sarajevo reported regular food supplement consumption.

Practitioners should be aware that a significant portion of gym users are consuming supplements regularly.

Self-prescription is the predominant method of food supplement use among gym users, with 40.3% reporting this practice.

Practitioners should consider the implications of self-prescription on supplement safety and effectiveness.

Males reported higher food supplement consumption compared to females.

Practitioners should tailor their advice and education on supplements considering gender differences.

43.5% of participants aged 40 and above in Bo District have at least one physiological risk factor for cardiovascular diseases, such as hypertension, obesity, or diabetes.

Health interventions should target older adults to reduce cardiovascular disease risk.

Interest in non-evidence-based practices was greater among women and Black/African American patients.

Healthcare providers should consider demographic factors when discussing weight loss options.

Interest in GLP-1s was associated with lower education and greater social norms.

Understanding educational background may help tailor discussions about GLP-1s.

Past use of non-evidence-based practices was associated with greater pharmaceutical distrust.

Addressing distrust in pharmaceuticals may improve patient engagement with evidence-based treatments.

Current human evidence on the effects of GLP-1 RAs on periodontal health is limited and observational.

Practitioners should be cautious in applying findings from limited human studies to clinical practice.

40.9% of participants demonstrated high adherence to medication, while 42.6% had low adherence.

Practitioners should be aware that adherence levels are suboptimal in this population.